Amgen Inc. (TSX:AMGN)
34.26
-0.21 (-0.61%)
Nov 13, 2026, 4:00 PM EST
Amgen Employees
Amgen had 31,500 employees as of December 31, 2025. The number of employees increased by 3,500 or 12.50% compared to the previous year.
Employees
31,500
Change (1Y)
3,500
Growth (1Y)
12.50%
Revenue / Employee
1.75M CAD
Profits / Employee
423.24K CAD
Market Cap
358.98B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 31,500 | 3,500 | 12.50% |
| Dec 31, 2024 | 28,000 | 1,300 | 4.87% |
| Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
| Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
| Dec 31, 2021 | 24,200 | -100 | -0.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Vireo Growth | 612 |
Amgen News
- 2 hours ago - Amgen price target raised to $430 from $400 at Barclays - TheFly
- 3 days ago - Amgen price target raised to $515 from $460 at Argus - TheFly
- 5 days ago - Amgen's experimental Sjogren's drug meets late-stage trial goal - Reuters
- 5 days ago - Amgen reports results from Phase 3 OASIZ-301 study of dazodalibep - TheFly
- 5 days ago - AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE - PRNewsWire
- 6 days ago - Amgen’s Repatha shows cost-effectiveness in cardiovascular study - TheFly
- 6 days ago - NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM - PRNewsWire
- 7 days ago - Novartis drops heart drug after it failed to prevent heart attacks - Stock Analysis